陈显春,王海久

晚期胆管癌预后极差，一线化疗失败后缺乏标准二线治疗方案。仑伐替尼作为多靶点酪氨酸激酶抑制剂，可通过抑制血管生成及肿瘤微环境重塑发挥抗肿瘤作用；免疫检查点抑制剂则通过解除肿瘤免疫抑制状态激活机体免疫应答。两者联合具有协同增效潜力，近年初步临床研究显示其在晚期胆管癌二线治疗中展现出一定疗效。本文综述仑伐替尼联合免疫检查点抑制剂的作用机制、临床研究进展、安全性及应用前景，为晚期胆管癌二线治疗提供新思路。

仑伐替尼；免疫检查点抑制剂；晚期胆管癌；二线治疗；联合用药

[1] Malka D,Borbath I,Lopes A,et al.Reply to letter comments on:Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer:an international,randomised,controlled,open-label,phase III umbrella trial(SAFIR-ABC10-Precision Medicine).[J]. ESMO open,2025,10(8):105536. [2] Zhou F,Chen W,Ruan L.Letter to the Editor Re:Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer:an international,randomized,controlled,open-label,phase III umbrella trial(SAFIR-ABC10-Precision Medicine).[J].ESMO open, 2025,10(8):105535. [3] 王开宇,郭天宇,张雷,等.恩沃利单抗联合卡培他滨治疗TERT突变型晚期胆管癌1例[J].中国新药杂志,2025,34(13):1402-1405. [4] Hallab E,Durham N J,Walker R,et al.Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma:a phase 2 clinical trial[J].Epigenetics Communications,2025,5(1):6-6. [5] Vrana E,Alothman A,Taylor L,et al.348P Molecular profiling success in advanced cholangiocarcinoma(CCA)based on tumour acquisition method[J].Annals of Oncology,2025,36(S1):S136-S136. [6] Passardi A,Borghi E,Parisi A,et al.340P Preliminary report on advanced biliary cancer receiving multimodality treatment in the immunotherapy era:A real-world multicenter experience[J].Annals of Oncology,2025,36(S1):S133-S133. [7] Sidabraite A,Mosert L P,Ahmed U,et al.Advancing Cholangiocarcinoma Diagnosis:The Role of Liquid Biopsy and CRISPR/Cas Systems in Biomarker Detection[J].Cancers,2025,17(13):2155-2155. [8] 刘宣.介入影像医学技术对晚期肝门部胆管癌姑息治疗效果的影响评价[C]//中国老年保健协会.长者“护航计划"——第三届中西医融合助力现代医学发展会议论文集.定州市人民医院;,2025:219-221. [9] Bianca K,Almut B,Claus L,et al.Highly elevated sepsis biomarkers in advanced cholangiocarcinoma without sepsis:A case report and literature review[J].Medicine,2025,104(21):e42115-e42115. [10] Mohan A,Sahai V.How I Treat Advanced Biliary Cancer[J].Advances in Oncology,2025,5(1):257-265. [11] Brar G,Shroff T R.Anti-PD-1 Therapy for Patients with Advanced Cholangiocarcinoma:Ready for Prime Time?[J].Journal of immunotherapy and precision oncology,2025,8(2):181-183. [12] Akkus E,Yasar A H,Rimassa L,et al.Efficacy and Toxicity of Pemigatinib in Advanced Cholangiocarcinoma Harboring FGFR Fusions or Rearrangements:A Systematic Review and Meta-analysis[J].Targeted Oncology,2025,20(3):1-15. [13] Malka D,Borbath I,Lopes A,et al.Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer:an international,randomised,controlled,open-label,phase III umbrella trial(SAFIR-ABC10-Precision Medicine).[J].ESMO open,2025, 10(5):104540. [14] 贾云明,耿家波,朱海波,等.介入影像医学技术对晚期肝门部胆管癌姑息治疗效果的影响[J].影像研究与医学应用, 2025, 9(07):176-178. [15] 李淳,马祖燚,孙嘉,等.晚期胆管癌系统治疗:全球指南的分歧与区域临床实践[J].外科理论与实践,2025,30(02):93-100. [16] Wang W,Xu L,Li P,et al.Cost-effectiveness analysis of pembrolizumab combined with gemcitabine and cisplatin for the first-line treatment for advanced cholangiocarcinoma[J].Heliyon,2025,11(6):e42553-e42553. [17] Daungsupawong H,Wiwanitkit V.Comment on"IL-21 and IL-33 May Be Effective Biomarkers to Predict the Efficacy of PD-1 Monoclonal Antibody for Advanced Cholangiocarcinoma".[J].Cancer biotherapy&radiopharmaceuticals,2025, [18] Michl M,Hagemeyer N,LooßM,et al.IDHIRA:a prospective,observational study on ivosidenib in patients with IDH1 R132-mutated advanced cholangiocarcinoma.[J].Future oncology(London,England),2025,21(9):1-8. [19] Ismail B I,Mlika M,Manai G,et al.Sister Mary Joseph's nodule:A rare metastasis of hilar cholangiocarcinoma:A new case report and review of the literature[J].Heliyon,2025,11(4):e42449-e42449. [20] 谢文哲,孙华朋,龚伟,等.晚期肝门部胆管癌综合方案降期､序贯手术治疗成功一例[J].肝胆胰外科杂志,2025,37(02):122-124. [21] Yan H,Deng Q,Meng Y,et al.IL-21 and IL-33 May Be Effective Biomarkers to Predict the Efficacy of PD-1 Monoclonal Antibody for Advanced Cholangiocarcinoma.[J].Cancer biotherapy&radiopharmaceuticals,2025, [22] Rohan T,Cechova B,Matkulcik P,et al.Prognostic factors for survival in patients with advanced cholangiocarcinoma treated with percutaneous transhepatic drainage.[J].Scientific reports,2025,15(1):2172. [23] Liao Z,Yao Z,Yang Z,et al.Comparative efficacy of targeted therapy,chemotherapy and their combination for advanced cholangio- carcinoma:a systematic review and network meta-analysis.[J].PeerJ,2025,13 e19386. [24] Castria D B T,Kim D R.Safety of current treatments for advanced cholangiocarcinoma.[J].Expert opinion on drug safety,2024,24(3):251-259. [25] 陈书德,林一鹏,徐伟华.晚期肝内胆管癌系统治疗的研究进展[J].腹部外科,2025,38(01):70-73+77. [26] Désert R,Goyal L,Baumert F T.Time for arginine methylation:PRMT5 inhibition to advance cholangiocarcinoma treatment.[J].Gut,2024, [27] 盛芳,徐芳,谢梦忆,等.晚期肝内胆管癌免疫治疗联合化疗的临床价值研究[J].中国肿瘤外科杂志,2024,16(05):509-513. [28] 赵海涛,王闪闪.胆囊癌转化治疗及序贯手术治疗的几个关键问题[J].中国实用外科杂志,2023,43(11):1214-1222. [29] 董雨龙,陶晨洁,娄成,等.首次疗效评估中肿瘤最长径之和变化对晚期肝内胆管癌化疗患者生存预后的预测价值[J].同济大学学报(医学版),2023,44(05):723-729. [30] 王然,俞远东.晚期胆管癌安罗替尼维持治疗的疗效及安全性分析[J].现代肿瘤医学,2023,31(17):3232-3236.

点击下载PDF